Literature DB >> 8578845

Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles.

H M Vordermeier1, A G Coombes, P Jenkins, J P McGee, D T O'Hagan, S S Davis, M Singh.   

Abstract

Tuberculosis remains a major public health burden which could be ameliorated by effective and well-defined subunit vaccines, particularly because the protective efficacy of current M. bovis BCG vaccines is both unpredictable and variable. The immunodominant 38 kDa antigen from Mycobacterium tuberculosis was entrapped in biodegradable poly (DL-lactide co-glycolide) (PLG) microparticles which served as a delivery system. Both cellular and humoral immune responses were assessed and compared with those obtained after immunization with the 38 kDa protein emulsified in incomplete Freund's adjuvant (IFA). Vaccination of mice with a single dose of antigen-loaded microparticles resulted in specific IgG titres peaking after five weeks comparable to those achieved after vaccination with protein emulsified in incomplete Freund's adjuvant (IFA). T-cell responses were found to be superior to those induced with antigen/IFA. The T- and B-cell epitope specificities ad judged with synthetic peptides were identical following immunization with antigen in microparticles or IFA. Differences in adjuvanticity were revealed by measuring antigen-specific IgG1, IgG2a and antigen-induced IFN-gamma secretion in vitro: substantially higher titres of IgG2a were observed following immunization with antigen/microparticles than with 38 kDa protein/IFA. This was paralleled by a tenfold higher secretion of IFN-gamma in mice injected with antigen/microparticles. Reduction in colony-forming units was not consistent in mice immunized with 38 kDa protein entrapped in microparticles which were subsequently infected with live tubercle bacilli. Taken together these results indicate that biodegradable PLG microparticles constitute a favorable candidate vaccine delivery system worthy of further assessment in the quest to develop better and defined agents protecting against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578845     DOI: 10.1016/0264-410x(95)00084-e

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.

Authors:  Avi-Hai Hovav; Yolanta Fishman; Herve Bercovier
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

3.  Protective efficacy of mycobacterial 71 kilodalton cell wall associated protein using poly (DL-lactide-co-glycolide) microparticles as carrier vehicles.

Authors:  N Dhiman; G K Khuller
Journal:  Indian J Clin Biochem       Date:  1997-12

4.  Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Ding Xu; Sherry L Kurtz; Jian Liu; Miriam Braunstein; David N McMurray; Anthony J Hickey
Journal:  Pharm Res       Date:  2007-07-27       Impact factor: 4.200

5.  Identification of new cytotoxic T-cell epitopes on the 38-kilodalton lipoglycoprotein of Mycobacterium tuberculosis by using lipopeptides.

Authors:  D P da Fonseca; D Joosten; R van der Zee; D L Jue; M Singh; H M Vordermeier; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.

Authors:  Christian Sänger; Andreas Busche; Gabriele Bentien; Ralf Spallek; Fatima Jonas; Andreas Böhle; Mahavir Singh; Sven Brandau
Journal:  BMC Cancer       Date:  2004-11-26       Impact factor: 4.430

7.  Preparation, characterization and immunological evaluation: canine parvovirus synthetic peptide loaded PLGA nanoparticles.

Authors:  Serap Derman; Zeynep Akdeste Mustafaeva; Emrah Sefik Abamor; Melahat Bagirova; Adil Allahverdiyev
Journal:  J Biomed Sci       Date:  2015-10-20       Impact factor: 8.410

8.  Polymorphism of MPT64 and PstS1 in Mycobacterium tuberculosis is not likely to affect relative immune reaction in human.

Authors:  Tongyang Xiao; Yi Jiang; Guilian Li; Hui Pang; Lili Zhao; Xiuqin Zhao; Kanglin Wan
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

9.  Monocytes and the 38kDa-antigen of mycobacterium tuberculosis modulate natural killer cell activity and their cytolysis directed against ovarian cancer cell lines.

Authors:  Nina Gottschalk; Stephan Lang; Rainer Kimmig; Mahavir Singh; Sven Brandau
Journal:  BMC Cancer       Date:  2012-10-04       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.